GlassScriptPhysician profile
Ernestine Johnson
NPI 1588057137
$2,175.35
in general payments reported to CMS, 2019-2025
29 companies · $817 in 2025
The $817 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,358 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,876 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,875.71 |
| Education | $299.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $205.40 | 2024 | Enbrel, Otezla, Prolia |
| Daiichi Sankyo INC. | $155.86 | 2024-2025 | Enhertu, Injectafer, Vanflyta |
| Janssen Biotech, INC. | $147.26 | 2024 | Simponi Aria, Tremfya, Remicade |
| Pfizer INC. | $137.62 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $136.10 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Sobi, INC | $136.00 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $132.64 | 2024 | Lupkynis |
| Takeda Pharmaceuticals U.S.A., INC. | $124.53 | 2024-2025 | Ninlaro, Fruzaqla |
| Tersera Therapeutics LLC | $117.29 | 2024-2025 | Zoladex, Xermelo |
| Lilly USA, LLC | $100.18 | 2024 | Taltz |
| Incyte Corporation | $95.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $87.37 | 2024 | |
| Eisai INC. | $84.69 | 2024-2025 | |
| Abbvie INC. | $81.17 | 2024-2025 | |
| Seagen INC. | $74.99 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $34.31 | 2024 | Tymlos |
| Legend Biotech USA INC. | $33.76 | 2025 | Carvykti |
| Genmab U.S., INC. | $32.66 | 2025 | Tivdak |
| Ani Pharmaceuticals, INC. | $30.08 | 2024 | Purified Cortrophin Gel |
| Celgene Corporation | $29.90 | 2024-2025 | Reblozyl |
| Beone Medicines USA, INC. | $28.73 | 2025 | Brukinsa |
| Pharmaessentia USA Corporation | $27.89 | 2025 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $23.78 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.39 | 2024 | |
| Gilead Sciences, INC. | $22.80 | 2025 | Trodelvy |
| Glaxosmithkline, LLC. | $22.01 | 2024 | Benlysta |
| Array Biopharma INC | $18.11 | 2025 | Mektovi, Tukysa, Braftovi |
| Ipsen Biopharmaceuticals, INC | $16.37 | 2025 | Onivyde |
| Pharmacosmos Therapeutics INC. | $15.46 | 2024 | Cosela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernestine Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.